Your browser doesn't support javascript.
Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants.
Meyer, Saskia; Blaas, Isaac; Bollineni, Ravi Chand; Delic-Sarac, Marina; Tran, Trung T; Knetter, Cathrine; Dai, Ke-Zheng; Madssen, Torfinn Støve; Vaage, John T; Gustavsen, Alice; Yang, Weiwen; Nissen-Meyer, Lise Sofie Haug; Douvlataniotis, Karolos; Laos, Maarja; Nielsen, Morten Milek; Thiede, Bernd; Søraas, Arne; Lund-Johansen, Fridtjof; Rustad, Even H; Olweus, Johanna.
  • Meyer S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.
  • Blaas I; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.
  • Bollineni RC; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.
  • Delic-Sarac M; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.
  • Tran TT; Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.
  • Knetter C; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.
  • Dai KZ; Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.
  • Madssen TS; Department of Circulation and Medical Imaging, NTNU, 7030 Trondheim, Norway.
  • Vaage JT; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway; Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.
  • Gustavsen A; Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.
  • Yang W; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.
  • Nissen-Meyer LSH; Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.
  • Douvlataniotis K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.
  • Laos M; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway; Institute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, 50411 Ta
  • Nielsen MM; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway.
  • Thiede B; Department of Biosciences, University of Oslo, 0371 Oslo, Norway.
  • Søraas A; Department of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.
  • Lund-Johansen F; Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway; ImmunoLingo Convergence Center, University of Oslo, 0372 Oslo, Norway.
  • Rustad EH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway. Electronic address: ehrustad@gmail.com.
  • Olweus J; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0379 Oslo, Norway; Institute of Clinical Medicine, University of Oslo, 0372 Oslo, Norway. Electronic address: johanna.olweus@medisin.uio.no.
Cell Rep ; 42(1): 111995, 2023 01 31.
Article in English | MEDLINE | ID: covidwho-2177162
ABSTRACT
The emergence of SARS-CoV-2 variants of concern (VOC) is driven by mutations that mediate escape from neutralizing antibodies. There is also evidence that mutations can cause loss of T cell epitopes. However, studies on viral escape from T cell immunity have been hampered by uncertain estimates of epitope prevalence. Here, we map and quantify CD8 T cell responses to SARS-CoV-2-specific minimal epitopes in blood drawn from April to June 2020 from 83 COVID-19 convalescents. Among 37 HLA ligands eluted from five prevalent alleles and an additional 86 predicted binders, we identify 29 epitopes with an immunoprevalence ranging from 3% to 100% among individuals expressing the relevant HLA allele. Mutations in VOC are reported in 10.3% of the epitopes, while 20.6% of the non-immunogenic peptides are mutated in VOC. The nine most prevalent epitopes are conserved in VOC. Thus, comprehensive mapping of epitope prevalence does not provide evidence that mutations in VOC are driven by escape of T cell immunity.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: Cell Rep Year: 2023 Document Type: Article Affiliation country: J.celrep.2023.111995

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: Cell Rep Year: 2023 Document Type: Article Affiliation country: J.celrep.2023.111995